prosper Obed chukwuemeka

Mr. prosper Obed chukwuemeka

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 January 2021 in Journal of Genetic Engineering and Biotechnology
Verified
Journal Article
Open access
PDF file
HUHaruna Isiyaku Umar
Haruna Isiyaku Umar
BSBushra Siraj
Bushra Siraj
AAAdeola Ajayi
Adeola Ajayi
TJTajudeen O. Jimoh
Tajudeen O. Jimoh
PCprosper Obed chukwuemeka
prosper Obed chukwuemeka
The World Health Organization has recently declared a new coronavirus disease (COVID-19) a pandemic and a global health emergency. The pressure to produce drugs and vaccines against the ongoing pandemic has resulted in the use of some drugs such as azithromycin, chloroquine (sulfate and phosphate), hydroxychloroquine, dexamethasone, favipiravir, remdesivir, ribavirin, ivermectin, and lopinavir/ritonavir. However, reports from some of the clinical trials with these drugs have proved detrimental on some COVID-19 infected patients with side effects more of which cardiomyopathy, cardiotoxicity, nephrotoxicity, macular retinopathy, and hepatotoxicity have been recently reported. Realizing the need for potent and harmless therapeutic compounds to combat COVID-19, we attempted in this study to find promising therapeutic compounds against the imminent threat of this virus. In this current study, 16 derivatives of gallic acid were docked against five selected non-structural proteins of SARS-COV-2 known to be a good target for finding small molecule inhibitors against the virus, namely, nsp3, nsp5, nsp12, nsp13, and nsp14. All the protein crystal structures and 3D structures of the small molecules (16 gallic acid derivatives and 3 control drugs) were retrieved from the Protein database (PDB) and PubChem server respectively. The compounds with lower binding energy than the control drugs were selected and subjected to pharmacokinetics screening using AdmetSAR server. 4-O-(6-galloylglucoside) gave binding energy values of − 8.4, − 6.8, − 8.9, − 9.1, and − 7.5 kcal/mol against Mpro, nsp3, nsp12, nsp13, and nsp15 respectively. Based on the ADMET profile, 4-O-(6-galloylglucoside) was found to be metabolized by the liver and has a very high plasma protein binding. The result of this study revealed that 4-O-(6-galloylglucoside) could be a promising inhibitor against these SAR-Cov-2 proteins. However, there is still a need for further molecular dynamic simulation, in vivo and in vitro studies to support these findings.

4 August 2022 in Cells
Verified
Journal Article
Open access
PDF file
HUHaruna Isiyaku Umar
Haruna Isiyaku Umar
AAAdeola Temitayo Ajayi
Adeola Temitayo Ajayi
NMNobendu Mukerjee
Nobendu Mukerjee
AAAbdullahi Aborode
Abdullahi Aborode
Mohammad Mehedi HasanMohammad Mehedi Hasan
Mohammad Mehedi Hasan
HRHabibur Rahman
Habibur Rahman
Heat shock protein 27 (HSP27) is a protein that works as a chaperone and an antioxidant and is activated by heat shock, environmental stress, and pathophysiological stress. However, HSP27 dysregulation is a characteristic of many human cancers. HSP27 suppresses apoptosis and cytoskeletal reorganization. As a result, it is recognized as a critical therapeutic target for effective cancer therapy. Despite the effectiveness of multiple HSP27 inhibitors in pre-clinical investigations and clinical trials, no HSP27 inhibitor has progressed to the anticancer phase of the development. These difficulties have mostly been attributable to existing anticancer therapies’ inability to target oncogenic HSP27. Highly selective HSP27 inhibitors with higher effective-ness and low toxicity led to the development of combination techniques that include computer-aided assisted therapeutic discovery and design. This study emphasizes the most recent results and roles of HSP27 in cancer and the potential for utilizing an anticancer chemical database to uncover novel compounds to inhibit HSP27.

23 April 2021 in Journal of Biomolecular Structure and Dynamics
Verified
Journal Article
Closed access
PCprosper Obed chukwuemeka
prosper Obed chukwuemeka
HUHaruna Isiyaku Umar
Haruna Isiyaku Umar
OIOpeyemi Iwaloye
Opeyemi Iwaloye
OOOluwaseyi Matthew Oretade
Oluwaseyi Matthew Oretade
COChristopher Busayo Olowosoke
Christopher Busayo Olowosoke
MEMichael Omoniyi Elabiyi
Michael Omoniyi Elabiyi
The dysregulation of cyclin-CDK6 interactions has been implicated in human breast cancer, providing a rationale for more therapeutic options. Recently, ATP-competitive inhibitors have been employed for managing breast cancer. These molecules, like most natural CDKs inhibitors, potently bind in the ATP-binding site of CDK6 to regulate trans-activation. Nonetheless, only a few numbers of these molecules are approved to mitigate breast cancer, thus, ensuring that the search for more selective inhibitors continues. In this study, we attempted to establish the selective predictive models for identifying potent CDK6 inhibitors against a human breast cancer cell-line using a dataset of fifty-two 1,3,4-thiadiazole derivatives. The significant eight descriptor hybrid QSAR models generated exhibited encouraging statistical attributes including R2> 0.70, Q2LOO > 0.70, Q2LMO > 0.60, Qfn2 > 0.6. Furthermore, the study designed new compounds based on the activity and structural basis for selectivity of compounds for CDK6. While demonstrating good potency and modest selectivity, the compound C16, which showed significantly high activity of 5.5607 µM and binding energy value of −9.0 Kcal/mol, was used as template for compounds design to generate 10 novel series of 1,3,4-thiadiazole analogues containing benzisoselenazolone scaffolds, with significant pharmacological activity and better selectivity for CDK6. By our rationale, four of the designed compounds (C16b, C16h, C16i, and C16j) with activity values of 6.2584 µM, 6.7812 µM, 6.4717 µM, and 6.2666 µM respectively, and binding affinities of −10.0 kcal/mol, −9.9 kcal/mol, −9.9 kcal/mol, and −9.9 kcal/mol respectively, may emerge as therapeutic options for breast cancer treatment after extensive in vitro and in vivo studies. Communicated by Ramaswamy H. Sarma

14 May 2021 in Journal of Biomolecular Structure and Dynamics
Verified
Journal Article
Closed access
PCprosper Obed chukwuemeka
prosper Obed chukwuemeka
HUHaruna Isiyaku Umar
Haruna Isiyaku Umar
OIOpeyemi Iwaloye
Opeyemi Iwaloye
OOOluwaseyi Matthew Oretade
Oluwaseyi Matthew Oretade
COChristopher Busayo Olowosoke
Christopher Busayo Olowosoke
FAFunmilayo Janet Adeojo
Funmilayo Janet Adeojo
At present, disrupting p53-MDM2 interactions through small molecule ligands is a promising approach to safe treatment and management of human cancer. Tumor cells unlike the normal cells, are rapidly evolving affecting the efficacy of many approved anti-cancer agents due to drug resistance. Therefore, identifying a potential anticancer compound is crucial. Pharmacophore based virtual screening, followed by molecular docking, ADMET evaluation, and molecular dynamics studies against MDM2 protein was investigated to identify potential ligands that may act as inhibitors. The model (AHRR_1) with survival score (4.176) was selected among the top ranked generated Pharmacophore hypothesis. Validation of the model hypothesis by an external dataset of actives and inactive compounds produced significant validation attributes including; AUC = 0.85, BEDROC = 0.56 at α = 20.0, RIE = 8.18, AUAC = 0.88, and EF of 6.2 at the top 2% of the dataset. The model was use for screening the ZINC database, and the top 1375 hits satisfying the model hypothesis were subjected to molecular docking studies to understand the molecular and structural basis of selectivity of compounds for MDM2 protein. A sub-set of 25 compounds with binding energy lower than the reference inhibitors were evaluated for pharmacokinetic properties. Four compounds (ZINC02639178, ZINC06752762, ZINC38933175, and ZINC77969611) showed the most desired pharmacokinetic profile. Lastly, investigation of the dynamic behaviour of leads-protein complexes through MD simulation showed similar RMSD, RMSF, and H-bond occupancy profile compared to a reference inhibitor, suggesting stability throughout the simulation time. However, ZINC02639178 was found to satisfy the molecular enumeration the most compared to the other three leads. It may emerge as potential treatment option after extensive experimental studies. Communicated by Ramaswamy H. Sarma Graphical Abstract

7 April 2023 in Molecular Diversity
Verified
Journal Article
Closed access
PDF file
OOOluwatoyin Folake Olukunle
Oluwatoyin Folake Olukunle
COChristopher Busayo Olowosoke
Christopher Busayo Olowosoke
AKAqsa Khalid
Aqsa Khalid
GOGrace Ayomide Oke
Grace Ayomide Oke
VOVictor Omoboyede
Victor Omoboyede
PCprosper Obed chukwuemeka
prosper Obed chukwuemeka

5 October 2021 in Chemical Papers
Verified
Journal Article
Closed access
PDF file
HUHaruna Isiyaku Umar
Haruna Isiyaku Umar
AAAdeola Ajayi
Adeola Ajayi
RBRidwan Opeyemi Bello
Ridwan Opeyemi Bello
HAHafsat Olateju Alabere
Hafsat Olateju Alabere
ASAfees Akinbode Sanusi
Afees Akinbode Sanusi
PCprosper Obed chukwuemeka
prosper Obed chukwuemeka